RY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. RY is sitting just above near-term support (~165.79) with weakening momentum (MACD histogram negative and expanding) and no Intellectia buy signals today. While fundamentals and Street targets are constructive, the current tape suggests better odds of a slightly lower entry over the next week than immediate upside. Action: HOLD today; only becomes a buy if it reclaims ~167.7–169.6 with improving momentum or cleanly holds support and reverses.
Trend/Momentum: Short-term momentum is bearish-to-neutral. MACD histogram is -0.62 and negatively expanding (selling pressure increasing). RSI(6) ~42.9 is neutral but leaning weak (not oversold). Moving averages are converging, signaling consolidation rather than a clean uptrend. Levels: Pivot 167.693 is the near-term line to regain for bullish control. Immediate support S1 165.787 (price is very close); if it breaks, next support S2 164.609. Upside resistance levels: R1 169.6 then R2 170.777. Tactical read: With price under the pivot and momentum deteriorating, risk/reward for an impatient entry is unfavorable unless you are specifically buying at/near S1 for a quick bounce.
Intellectia Proprietary Trading Signals
Quant/Pattern note: Similar-pattern stats imply a mild negative skew near-term (next week expectation -2.39%), which aligns with the current MACD weakness.
Strong latest reported quarter (2025/Q4): revenue +18.4% YoY, net income +28.22% YoY, EPS +29.55% YoY.
Analyst optimism and rising targets (multiple raises/upgrades), supporting the medium-term narrative.
Capital return tailwinds cited by analysts (share repurchases/capital generation).
Next catalyst: Earnings on 2026-02-25 (pre-market) could reset sentiment if results/guide beat expectations.
Near-term technical weakness: MACD worsening and price below pivot (~167.
increases odds of a support retest/break (165.8 then 164.6).
No supportive news flow in the last week (no fresh positive catalyst to reverse momentum).
One notable cautious voice: Jefferies downgraded to Hold citing fair valuation after a rally and lingering credit pressure risk for Canadian banks.
Elevated implied volatility suggests the market is bracing for uncertainty (and can pressure near-term returns if the stock chops).
Latest quarter: 2025/Q4. Growth: Revenue 16.588B (+18.40% YoY), Net Income 5.293B (+28.22% YoY), EPS 3.77 (+29.55% YoY). Interpretation: Strong YoY acceleration in profitability and EPS indicates improving operating leverage and/or credit/expense dynamics versus the prior year, supportive for the medium-term investment case.
Recent trend: Predominantly positive. Multiple firms raised price targets and reiterated Buy/Outperform/Overweight (Scotiabank, BofA, National Bank, Canaccord, Barclays, UBS). TD Securities and TD Cowen upgraded to Buy (2025-12-04). One counterpoint: Jefferies downgraded to Hold (2025-11-25) on valuation and credit-pressure concerns. Wall Street pros: Strong earnings/operating leverage, stable credit outlook (per bullish notes), capital generation and buybacks, synergy/efficiency themes. Wall Street cons: After a rally, valuation viewed as fair by at least one firm; Canadian bank credit pressures may not be fully resolved. Influential/political trading check: No recent congress trading data available; hedge funds and insiders are neutral (no significant recent trends).
